Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is a Canadian healthcare company.
Technical charts show the company's stock is basing and flashing new signals to buy. Investors and analysts can view a key video update on the company's new and very significant growth plan here.
This plan will make the company's main business diagnosing Alzheimer's disease, using high-technology brain-optimized Positron Emission Tomography (PET) scans for diagnosis, with the goal of capturing a US$6.9 billion emerging market. Medicare, Medicaid, and private insurance will cover the cost for the patients, making the target market both enormous and enticing.
Algernon to Open the First Brain-Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building – Globe News Wire, March 23, 2026.
Investors and analysts can read more here.
Florida's Retirement Community
Alzheimer's affects older people, and Florida has a huge retirement community.
They are the target market for the company's new flagship clinic, with the doors expected to open for patients in just a few months.
Investors and analysts can read the news release on the Novascan Neuroimaging Clinics here.
Alzheimer's: A New Direction for Algernon
The company is entering the Alzheimer's Disease (AD) diagnostic market segment with plans to establish a network of dedicated neuroimaging medical clinics in the U.S., utilizing the most advanced, FDA-cleared brain-specific PET scanner to focus on early-stage detection of the disease.
The Vision
A Focus on Alzheimer's
Funding in Place for the Expansion
Investors and analysts can read the funding details here:
Treatment with DMT, A Natural Psychedelic Compound for Brain Injury
Alongside its work in the Alzheimer's Disease market, Algernon was the first company in the world to investigate DMT for stroke and traumatic brain injury recovery.
DMT is a natural compound that may promote neuroplasticity in the brain after injuries like a concussion or stroke.
It is part of the tryptamine family, which also includes psilocybin and psilocin. DMT increases brain-derived neurotropic factor (BDNF), which is critical to healing after a stroke or traumatic brain injury.
AGN NeuroScience
Algernon NeuroScience (AGN Neuro) is a wholly owned private subsidiary of Algernon Pharmaceuticals and has been established to advance its DMT program for stroke and traumatic brain injury (TBI).
PET Scan Launch Partners
The launch partners are highly respected players in the U.S. health care space.
Recent Developments and FDA Approvals
The FDA has approved two new AD antibody treatment therapies developed by Eli Lilly (Kinsula) and Eisai and Biogen (Leqembi). Both are covered by U.S. Medicare, Medicaid, and private insurance.
These therapies can clear amyloid plaque from the brain and help slow down the progression of the disease.
The FDA has also approved the new ultracompact Oncovision CareMiBrain™ brain-specific, Positron Emission Tomography (PET) scanner system, which can confirm amyloid plaque build-up, a prerequisite established by the FDA prior to the administration of the new AD drug.
Small Cap Health Care Stocks Set to Soar?
The Invesco/S&P small caps health care ETF.
There is bullish technical action on this key weekly chart:
- A bullish triangle is in play.
- Stochastics (14,7,7 series is oversold for only the fourth time since 2023.
- RSI is almost oversold and is turning up.
Low market capitalization stocks like Algernon can benefit from a surge in the overall health care sector.
Another Key Small Caps Healthcare Chart
This daily chart shows not only bull wedge action, but a breakout today!
Note the significant volume just a few weeks ago. Small-cap stocks look set to surge, and with the launch of Algernon's Novascan clinics, the stock should be on every speculator's watch list… watching for a burst in volume that signals launch day is here.
A Key Long-Term Algernon Chart
On this weekly chart, a classic double bottom is in play in the CA$0.05 area.
Stochastics (14,5,5 series) is massively oversold and starting to flash a crossover buy signal.
Significant rallies have followed recent bursts of volume… and another burst is in play now.
Shares Outstanding
Algernon Pharmaceuticals Inc. has approximately 46.5 million to 54.1 million shares outstanding.
Significant Shareholders
The largest shareholder is AlphaNorth Asset Management, holding over 7% (approx. 2.6 million shares).
Other key insiders include CEO Christopher Moreau and CFO James Kinley.
Another Bullish Chart
There's a huge bullish divergence between the key FORCE index and the price on this daily chart.
RSI is also massively oversold.
Big volume suggests a changing of the guard… from weak hands to strong.
A Momentum-Oriented Breakout Is Next?
On this weekly line chart, the ADX momentum indicator has turned up, bullishly leading the price.
Stock price at time of writing: Approx. CA:$0.045
Short-Term Technical Price Target: CA$0.08
Medium-Term Technical Price Target: CA$0.17
Long-Term Technical Price Target: CA$0.40
Technical Rating: Strong Speculative Buy
You can view the company's investor presentation here.
Company Website: https://www.algernonhealth.com/
| Want to be the first to know about interesting Life Sciences Tools & Diagnostics and Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Algernon Health has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
-
For this article, Algernon Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Algernon Health.
- Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
- Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company.
For additional disclosures, please click here.
